Aquestive Therapeutics. has filed a patent for pharmaceutical compositions of epinephrine and its prodrugs with enhanced permeation properties. The patent describes administering the compositions through an oral film with specific residence times for effective delivery of the active component. GlobalData’s report on Aquestive Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aquestive Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aquestive Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Aquestive Therapeutics's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Oral film for administering epinephrine with enhanced permeation properties

Source: United States Patent and Trademark Office (USPTO). Credit: Aquestive Therapeutics Inc

The patent application (Publication Number: US20240016734A1) describes a method for administering a pharmaceutical composition using an oral film containing a polymeric matrix, a pharmaceutically active component (such as epinephrine or its prodrug), and an adrenergic receptor interacter. The film is placed in the oral mucosa for a specific residence time, allowing the delivery of the active component. The residence time can vary from 0 to 4 minutes, with corresponding pharmacokinetic parameters like AUC (area under the curve) for different time intervals.

Furthermore, the method includes variations in the composition, such as the inclusion of multiple adrenergic receptor interacters, different types of adrenergic receptor interacters like aromatic compounds or phytoextracts, and absorbant components like amorphous silicon dioxide. The polymeric matrix can consist of various polymers like polyethylene oxide or cellulosic polymers. The method also covers the administration of epinephrine through a swallowable composition, including a prodrug of epinephrine, to deliver the active component through the digestive tract. Different parameters like Tmax (time to maximum concentration) and AUC are specified for this method as well, along with variations in residence time and absorption characteristics based on food intake. Overall, the patent application outlines a detailed method for administering epinephrine using innovative oral film technology with specific pharmacokinetic parameters and composition variations.

To know more about GlobalData’s detailed insights on Aquestive Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies